M&A / Deals Symeres and Ambagon collaborate for colorectal cancer molecules Pharmaceutical Business ReviewThe partnership aims to explore a new class of small molecules, called molecular glues, which enable or stabilise interactions between proteins.M&A / DealsOncologyRead full story pharminent April 1, 2026 (Last updated: April 1, 2026) Pharmaceutical Business Review The partnership aims to explore a new class of small molecules, called molecular glues, which enable or stabilise interactions between proteins. M&A / DealsOncologyRead full story Post navigation Previous: Telomir seeks FDA approval for Telomir-1 to treat breast cancerNext: Eli Lilly outlays $7.8bn to acquire sleep drug biotech Centessa Related Stories M&A / Deals BioMarin spends up to $490m for Alesta’s bone disease candidate pharminent August 19, 2026 M&A / Deals J&J hands lymphoma bispecific CAR T back to AbelZeta pharminent August 17, 2026 M&A / Deals Novo Nordisk and AWS form AI partnership to speed drug discovery pharminent August 17, 2026
